DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (2032)

Chronic Obstructive Pulmonary Disease | Unmet Need | Detailed, Expanded Analysis

Chronic Obstructive Pulmonary Disease | Unmet Need | Detailed, Expanded Analysis

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

The chronic obstructive pulmonary disease (COPD) market is becoming increasingly crowded, but significant unmet need remains due to the lack of a disease-modifying therapy. In recent years, several new combination therapies have been approved for the treatment of COPD, further increasing the competition. Although these new therapies perform well on a variety of clinical end points, most offer only incremental improvements, and none have yet demonstrated a statistically significant decrease in all-cause mortality. Owing to the high level of unmet need in COPD, significant clinical and commercial opportunity remains for therapies that can provide a decrease in all-cause mortality, number of exacerbations, or improvement on several clinically important end points, including FEV1 and frequency of exacerbations, compared with current standards of care.

Table of contents

  • Detailed, Expanded Analysis
    • Treatment Drivers and Goals
      • Overview
      • Treatment Drivers and Goals
        • Methodology
        • Physician Weighting of Clinical and Non-Clinical Attributes
        • Rationale for Treatment Drivers and Goals Selection
      • Physician Rating of Treatment Drivers and Goals in Chronic Obstructive Pulmonary Disease
        • Efficacy
        • Convenience of Administration
        • Non-Clinical Factors
      • Stated Versus Derived Importance of Treatment Drivers and Goals
    • Product Performance Against Treatment Drivers and Goals
      • Overview
      • Rationale for Drug Selection
      • Current Brand Performance on Key Treatment Drivers and Goals
        • Efficacy
        • Convenience of Administration
        • Non-Clinical Factors
    • Assessment of Unmet Need
      • Overview
      • Overall Satisfaction with Current Treatment
      • Physician Rating of Unmet Need in Chronic Obstructive Pulmonary Disease
        • Efficacy
        • Convenience of Administration
        • Non-Clinical Factors
      • Unmet Need in Chronic Obstructive Pulmonary Disease and Related Indications
    • Opportunity Analysis
      • Areas of Opportunity in the Chronic Obstructive Pulmonary DiseasMarket and Emerging Therapy Insights
        • Opportunity: A Combination Therapy That Improves Overall Survival
        • Opportunity: A Biologic or Small-Molecule Therapy That Reduces Inflammation and Exacerbations
        • Opportunity: Therapies That Outperform Current Drugs on FEV1 and TDI Focal Score
        • Opportunity: Therapies That Are More Convenient and Have a Decreased Dosing Burden
    • Target Product Profiles
      • Assessing Drug Development Opportunities
      • Target Product Profile Methodology
      • Attribute Importance and Part-Worth Utilities
      • Conjoint Analysis-Based Simulations of Market Scenarios
        • Scenario 1
        • Scenario 2

Already a Client? Log in to access this report.

  • Pub Date: May 2016
  • Author(s): Kristine Mackin, PhD
  • Kristine Mackin, is an analyst on the immune and inflammatory disorders team at Decision Resources Group. She currently focuses on respiratory diseases, including asthma and COPD. She holds a doctorate in biochemistry from Brandeis University, where she studied the evolution of bacteriorhodopsin and the relationship between type I and type II rhodopsins. During her in Chemistry at Carleton College, she researched proinsulin processing. Prior to joining DRG, Dr. Mackin was involved with literature and market research for a new company pitch during an internship at Puretech Ventures in Boston, MA.

Purchase Report

Recent reports:
You may also be interested in: